Passage Bio
Update in progressPASG (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Passage Bio is a genetic medicines company focused on developing gene therapies for central nervous system diseases. Its programs include PBFT02 (progranulin/GRN for frontotemporal dementia due to progranulin deficiency), PBGM01 (GLB1/ß-galactosidase for infantile GM1), PBKR03 (Krabbe disease), PBML04 (metachromatic leukodystrophy), and PBAL05 (ALS), plus others for Huntington’s disease. It collaborates with UPenn’s Gene Therapy Program and Catalent, founded in 2017 and based in Philadelphia.
Company score
- Sentiment
- 0.04
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.01
- Governance
- -0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.02
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.01
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!